SAN DIEGO, June 29, 2015 /PRNewswire/ -- aTyr Pharma, Inc.
(Nasdaq: LIFE), a biotherapeutics company engaged in the discovery
and development of Physiocrine-based therapeutics to address severe
rare diseases, today announced that it has been added to the
Russell 2000®, Russell 3000® and Russell Global Indexes as part of
Russell Investments' annual reconstitution that took place after
market close on June 26, 2015.
The Russell 2000® Index measures the performance of
the small-cap segment of the U.S. equity market and is a subset of
the Russell 3000®, representing approximately 10 percent of
the total market capitalization of that index. Membership in
the Russell 2000® Index includes automatic inclusion in the
appropriate growth and style indexes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for both
passive and active investment strategies. Russell Investments
determines membership for each index based primarily on objective
market capitalization rankings and style attributes. More
than $5.7 trillion in assets are currently benchmarked to
the Russell family of indexes.
For more information on the Russell reconstitution, please see
the FTSE Russell website: www.ftserussell.com.
About aTyr Pharma
aTyr Pharma is engaged in the
discovery and clinical development of innovative medicines for
patients suffering from severe rare diseases using its knowledge of
Physiocrine biology, a newly discovered set of physiological
modulators. The Company's lead candidate, Resolaris™, is a
first-in-class intravenous protein therapeutic for the treatment of
rare myopathies with an immune component. Resolaris™ is currently
in a Phase 1b/2 clinical trial in adult patients with
facioscapulohumeral muscular dystrophy (FSHD). Trials are planned
in additional indications, including early onset FSHD and
limb-girdle muscular dystrophy (LGMD) 2B. Trials are also planned
for indications in interstitial lung disease (ILD). To protect this
pipeline, aTyr built an intellectual property estate comprising 45
issued or allowed patents and over 240 pending patent applications
that are solely owned or exclusively licensed by aTyr. aTyr's key
programs are currently focused on severe, rare diseases
characterized by immune dysregulation for which there are currently
limited or no treatment options. The Company was founded by
Professors Paul Schimmel, Ph.D., and
Xiang-Lei Yang, Ph.D., two leading
aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Any statements in this
release that are not historical facts may be considered such
"forward-looking statements." Such forward looking statements,
which represent management's intent, belief, or current
expectations, involve risks and uncertainties and other factors
that could cause actual results and the timing of certain events to
differ materially from future results expressed or implied by such
forward-looking statements. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include the Company's ability to raise additional
funding, its ability to develop or commercialize current or new
product candidates, uncertainties and delays inherent in
pre-clinical studies and clinical trials, unexpected new data,
safety and technical issues, competition, and market conditions.
These and additional risks and uncertainties are more fully
described in the Company's filings with the Securities and Exchange
Commission, including its most recent Quarterly Report on Form
10-Q. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. The
Company disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
For more information, please
visit http://www.atyrpharma.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/atyr-pharma-added-to-russell-2000-3000-and-global-indexes-300105928.html
SOURCE aTyr Pharma, Inc.